- You need to sign in or sign up before continuing.
0
0
10/16/22 at 2:29pm
Organization
Hcplive.com
Author
Giuliana Grossi
39 words
0
Comments
The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.
You are the first to view
https://www.hcplive.com/view/tirzepatide-vs-semaglutide-tina-thethi-differences-seen-diabetes-obesity
Create an account
or login to join the discussion